:: Volume 5, Issue 3 (9-2016) ::
Int J Med Invest 2016, 5(3): 111-116 Back to browse issues page
The Effect of MMP9 in the Development of Colorectal Cancer Progression
Anahita Nosrati * , Omid Emadian , Mahdi Jafarinejad
1Department of pathology, Gastrointestinal cancer research center, Imam Khomeini hospital, Mazandaran university of medical sciences,Iran.
Abstract:   (8103 Views)
Objective: Matrix metalloprotease 9 (MMP9) is a group of proteolytic enzymes that mediate breaking down the components of the fibrillar extracellular matrix during tissue rearrangement,physical,biological and pathological conditions such as growth, wound healing, inflammation and tumor progression. To investigate the association of these markers with clinicopathologic features and survival of colorectal cancers(CRC),we examined its expression in colorectal cancer tissues. Methods: The expression of MMP9 in 91 paraffin embedded specimens of colorectal cancer and normal tissue adjacent to the tumor of patients referred to Imam Khomeini Hospital in Sari,Iran was studied immunohistochemically and the relationship between the clinical data and pathological features were considered,too. Result: 91 samples (43 women and 48 men) were studied including 6 mucinous carcinoma and 88 adenocarcinoma. MMP9 expression was negative and positive in 31 and 66 cases respectively. Expression of MMP9 in normal tissue around the tumor was 5.5%. Our finding revealed that the MMP9 correlated significantly with tumor depth (p-value: 0.033) and metastasis to lymph node (p-value: 0.007). The association of MMP9 expression with the other clinicopathologic factors was not statistically significant (p-value> 0.05). Conclusion: According to this study,the relationship between the expression of MMP9 with lymph node metastasis and depth of tumor was observed. To confirm the result, vast studies with more samples and also with the other matrix metalloproteinase proteases is recommended.
Keywords: Colorectal Cancer, MMP9, Clinicopathology, Immunohistochemistry, Metastasis
Full-Text [PDF 989 kb]   (2039 Downloads)    
Type of Study: Research | Subject: General
References
1. 1.Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55(2):74-108. 2.Van Der Jagt MF, Wobbes T, Strobbe LJ, Sweep FC, Span PN. Metalloproteinases and their regulators in colorectal cancer. J Surg Oncol. 2010;101(3):259-69. 3.Radmard AR. Five common cancers in Iran. Arch Iran Med. 2010;13(2):143-6. 4.Hua H, Li M, Luo T, Yin Y, Jiang Y. Matrix metalloproteinases in tumorigenesis: an evolving paradigm. Cell Mol Life Sci. 2011;68(23):3853-68. 5.Nosrati A, Naghshvar F, Torabizadeh Z, Salehi F. Correlation of Colorectal cancer stem cell marker CD24 expression with clinicopathologic features and survival of patients with colorectal cancer. Govaresh. 2014;19(2):86-94. 6.Vu TH, Werb Z. Matrix metalloproteinases: effectors of development and normal physiology. Genes Dev. 2000;14(17):2123-33. 7.Meijer MJ, Mieremet-Ooms MA, van der Zon AM, van Duijn W, van Hogezand RA, Sier CF, et al. Increased mucosal matrix metalloproteinase-1, -2, -3 and -9 activity in patients with inflammatory bowel disease and the relation with Crohn's disease phenotype. Dig Liver Dis. 2007;39(8):733-9. 8.Sutnar A, Pesta M, Liska V, Treska V, Skalicky T, Kormunda S, et al. Clinical relevance of the expression of mRNA of MMP-7, MMP-9, TIMP-1, TIMP-2 and CEA tissue samples from colorectal liver metastases. Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine. 2006;28(5):247-52. 9.GUZIŃSKA-USTYMOWICZ K. MMP-9 and cathepsin B expression in tumor budding as an indicator of a more aggressive phenotype of colorectal cancer (CRC). Anticancer Res. 2006;26(2B):1589-94. 10.Groblewska M, Siewko M, Mroczko B, Szmitkowski M. The role of matrix metalloproteinases (MMPs) and their inhibitors (TIMPs) in the development of esophageal cancer. Folia Histochem Cytobiol. 2012;50(1):12-9. 11.Langenskiöld M, Holmdahl L, Falk P, Ivarsson M-L. Increased plasma MMP-2 protein expression in lymph node-positive patients with colorectal cancer. Int J Colorectal Dis. 2005;20(3):245-52. 12.Chu D, Zhao Z, Zhou Y, Li Y, Li J, Zheng J, et al. Matrix metalloproteinase-9 is associated with relapse and prognosis of patients with colorectal cancer. Ann Surg Oncol. 2012;19(1):318-25. 13.Koskensalo S, Hagström J, Linder N, Lundin M, Sorsa T, Louhimo J, et al. Lack of MMP-9 expression is a marker for poor prognosis in Dukes’ B colorectal cancer. BMC Clin Pathol. 2012;12(1):24. 14.Li C-Y, Yuan P, Lin S-S, Song C-F, Guan W-Y, Yuan L, et al. Matrix metalloproteinase 9 expression and prognosis in colorectal cancer: a meta-analysis. Tumor Biology. 2013;34(2):735-41. 15.Jensen SA, Vainer B, Bartels A, Brünner N, Sørensen JB. Expression of matrix metalloproteinase 9 (MMP-9) and tissue inhibitor of metalloproteinases 1 (TIMP-1) by colorectal cancer cells and adjacent stroma cells–associations with histopathology and patients outcome. Eur J Cancer. 2010;46(18):3233-42. 16.Yang B, Tang F, Zhang B, Zhao Y, Feng J, Rao Z. Matrix metalloproteinase-9 overexpression is closely related to poor prognosis in patients with colon cancer. World J Surg Oncol. 2014;12(1):24. 17.Buhmeida A, Bendardaf R, Hilska M, Collan Y, Laato M, Syrjänen S, et al. Prognostic significance of matrix metalloproteinase-9 (MMP-9) in stage II colorectal carcinoma. J Gastrointest Cancer. 2009;40(3-4):91-7. 18.Liabakk N-B, Talbot I, Smith RA, Wilkinson K, Balkwill F. Matrix metalloprotease 2 (MMP-2) and matrix metalloprotease 9 (MMP-9) type IV collagenases in colorectal cancer. Cancer Res. 1996;56(1):190-6. 19.Loesch M, Zhi HY, Hou SW, Qi XM, Li RS, Basir Z, et al. p38gamma MAPK cooperates with c-Jun in trans-activating matrix metalloproteinase 9. J Biol Chem. 2010;285(20):15149-58. 20.Papageorgis P, Cheng K, Ozturk S, Gong Y, Lambert AW, Abdolmaleky HM, et al. Smad4 inactivation promotes malignancy and drug resistance of colon cancer. Cancer Res. 2011;71(3):998-1008. 21.Zhang B, Halder SK, Kashikar ND, Cho YJ, Datta A, Gorden DL, et al. Antimetastatic role of Smad4 signaling in colorectal cancer. Gastroenterology. 2010;138(3):969-80. e3. 22.Garg P, Sarma D, Jeppsson S, Patel NR, Gewirtz AT, Merlin D, et al. Matrix metalloproteinase-9 functions as a tumor suppressor in colitis-associated cancer. Cancer Res. 2010;70(2):792-801. 23.Choi D, Lee HW, Hur KY, Kim JJ, Park G-S, Jang S-H, et al. Cancer stem cell markers CD133 and CD24 correlate with invasiveness and differentiation in colorectal adenocarcinoma. World journal of gastroenterology: WJG. 2009;15(18):2258. 24.THIS I, editor Surgical Pathology of Carcinoma of the Colon and Rectum. Semin Oncol; 1991. 25.Mohiuddin M, Ahmed MM, editors. Critical issues in the evolving management of rectal cancer. Semin Oncol; 1997. 26.Oladipo O, Conlon S, O'Grady A, Purcell C, Wilson C, Maxwell P, et al. The expression and prognostic impact of CXC-chemokines in stage II and III colorectal cancer epithelial and stromal tissue. Br J Cancer. 2011;104(3):480-7. 27.Kemper K. Molecular identification and targeting of colorectal cancer stem cells2012. 28.Curran S, Dundas SR, Buxton J, Leeman MF, Ramsay R, Murray GI. Matrix metalloproteinase/tissue inhibitors of matrix metalloproteinase phenotype identifies poor prognosis colorectal cancers. Clin Cancer Res. 2004;10(24):8229-34. 29.Jenab M, Bueno-de-Mesquita HB, Ferrari P, van Duijnhoven FJ, Norat T, Pischon T, et al. Association between pre-diagnostic circulating vitamin D concentration and risk of colorectal cancer in European populations: a nested case-control study. BMJ. 2010;340. 30.Fidler IJ. The pathogenesis of cancer metastasis: the'seed and soil'hypothesis revisited. Nature Reviews Cancer. 2003;3(6):453-8. 31.Westermarck J, KÄHÄRI V-M. Regulation of matrix metalloproteinase expression in tumor invasion. The FASEB Journal. 1999;13(8):781-92. 32.Murphy G, Docherty AJ. The matrix metalloproteinases and their inhibitors. Am J Respir Cell Mol Biol. 1992;7:120-. 33.Wilson PM, LaBonte MJ, Lenz H-J. Molecular markers in the treatment of metastatic colorectal cancer. The Cancer Journal. 2010;16(3):262-72. 34.Gorden DL, Fingleton B, Crawford HC, Jansen DE, Lepage M, Matrisian LM. Resident stromal cell‐derived MMP‐9 promotes the growth of colorectal metastases in the liver microenvironment. Int J Cancer. 2007;121(3):495-500.

XML     Print

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Volume 5, Issue 3 (9-2016) Back to browse issues page